The IPO, with a face value of Rs 10 per equity share, is a mix of fresh issue of up to 50,00,400 equity shares with an offer of sale up to 11,00,400 equity shares
FinTech BizNews Service
Mumbai, May 21, 2025: Mumbai-based healthcare focused company Influx Healthtech Limited has filed its Draft Red Herring Prospectus with for its initial public offering (IPO) in NSE Emerge.
The IPO, with a face value of Rs 10 per equity share, is a mix of fresh issue of up to 50,00,400 equity
shares with an offer of sale up to 11,00,400 equity shares by Munir Abdul Ganee Chandniwala. The
offer also includes a reservation for a subscription by market makers in the market maker reservation
portion.
The offer is being made through the book-building process, wherein not more than 50% of the net
offer shall be available for allocation on a proportionate basis to qualified institutional buyers, not less
than 15% of the net offer shall be available for allocation to non-institutional bidders, and not less
than 35% of the net offer shall be available for allocation to retail individual bidders.
The proceeds from its fresh issuance will be utilized to the extent of Rs 13.23 crore for purchase of
Machinery for setting up of new manufacturing facility for Nutraceutical Division; Rs 4.10 crore for
purchase of Machinery for setting up of new manufacturing facility for Veterinary Food Division; Rs
2.75 crore for Purchase of Machineries for Homecare and Cosmetic Division.
Mumbai-based Influx Healthtech Limited was established in 2020 by Mr. Munir Abdul Ganee
Chandniwala, the company has established itself as a reliable Contract Development and
Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across
various industries.
The company operates manufacturing facilities located in Thane, Maharashtra, and has an expertise
that spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal
Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients
(APIs), and finished dosage forms, including tablets, capsules, and injectables.
The company's manufacturing division offers Dietary/Nutritional Supplement, Cosmetics, and
Ayurvedic / Herbal formulations. It also provides customized products tailored to meet its clients'
specific needs. It has a long-standing relationship with clients which includes Bling Brands Private
Limited, Evoq Business Ventures LLP, HSHS Nutraceuticals Limited, Bruder Life Science, and Bigflex
Lifescience Private Limited.
Influx Healthtech’s revenue from operations increased by 31.44% from Rs 76.05 crore in the financial
year ended March 31, 2023 to Rs 99.97 crore in the financial year ended March 31, 2024. Profit after
tax increased from Rs 7.20 crore in the financial year ended March 31, 2023 to Rs 11.22 crore in the
financial year ended March 31, 2024.
For the seven months ended November 30, 2024, revenue from operations stood at Rs 62.75 crore,
and profit after tax stood at Rs 8.04 crore.
Rarever Financial Advisors Private Limited is the sole lead manager, and Maashitla Securities Private
Limited is the registrar of the issue.
